Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Cyclin E1 Positivity Predicts Response to Azenosertib in Platinum-Resistant Ovarian Cancer
March 16th 2025, 4:40pm
Patients with cyclin E1–positive platinum-resistant ovarian cancer experienced a greater response to azenosertib vs the overall DENALI population.
Avutometinib With Defactinib Exceeds Response Threshold in Advanced Mesonephric Gynecologic Cancer
March 16th 2025, 4:17pm
The combination of avutometinib and defactinib has previously shown activity in patients with low-grade serous ovarian cancer.
Pembrolizumab Plus Olaparib Improves PFS in BRCA Wild-Type Ovarian Cancer
March 16th 2025, 3:50pm
The KEYLYNK-001 trial found improved PFS among patients with advanced ovarian cancer given pembrolizumab/olaparib.
Dr Grisham on the Efficacy of Avutometinib Plus Defactinib in Gynecologic Mesonephric Cancer
March 16th 2025, 11:05am
Rachel N. Grisham, MD, discusses the efficacy of avutometinib plus defactinib in patients with advanced or recurrent gynecologic mesonephric cancer.
Dr Van Gorp on the Long-Term Efficacy of Mirvetuximab Soravtansine in FRα+ Platinum-Resistant Ovarian Cancer
March 16th 2025, 10:24am
Toon Van Gorp, MD, PhD, discusses the efficacy of mirvetuximab soravtansine in FRα-positive platinum-resistant ovarian cancer after 30.5 months of follow-up.
Zimberelimab Plus Lenvatinib Shows Activity in ICI-Pretreated Advanced Cervical Cancer
March 15th 2025, 8:15pm
The combination of zimberelimab and lenvatinib had antitumor activity and a manageable safety profile in pretreated advanced cervical cancer.
Afuresertib Plus Paclitaxel Does Not Elicit Substantial Clinical Benefit in Platinum-Resistant Ovarian Cancer
March 15th 2025, 8:05pm
Afuresertib combined with paclitaxel did not elicit PFS or OS benefits vs paclitaxel alone in patients with unselected platinum-resistant ovarian cancer.
Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer
March 15th 2025, 4:40pm
Olaparib maintenance following durvalumab plus chemotherapy improved PFS in different subgroups of pMMR endometrial cancer.
Pembrolizumab Plus Concurrent Chemoradiotherapy Improves OS, PFS2 in Advanced Cervical Cancer
March 15th 2025, 4:00pm
The addition of pembrolizumab to chemoradiotherapy prolonged survival and time to second progression in patients with locally advanced cervical cancer.
Cadonilimab Plus Lenvatinib Proves Active in Platinum-Pretreated, Advanced Endometrial Cancer
March 15th 2025, 3:23pm
Cadonilimab plus lenvatinib showed promise as therapy for patients with advanced endometrial cancer and disease progression on prior platinum therapy.
Nivolumab Yields High Clinical CR Rates Allowing for Surgery Omission in dMMR/MSI-H Endometrial Cancer
March 15th 2025, 3:00pm
Nivolumab elicited PR/CRs in all patients treated with resectable dMMR endometrial cancer and no patients experienced disease recurrence during follow-up.
Anti-CD38-CAR-γδ T Cells Show Preclinical Cytotoxicity in Myeloma
March 12th 2025, 2:00pm
ESMO Targeted Anticancer Therapies Congress
Preclinical cytotoxicity was demonstrated with anti-CD38-CAR-gamma-delta T cells in multiple myeloma.
MT-8421 Displays Acceptable Safety Profile in First-in-Human Trial for Advanced Solid Tumors
March 11th 2025, 9:03pm
ESMO Targeted Anticancer Therapies Congress
MT-8421, a novel engineered toxin body targeting CTLA-4, was not associated with grade 4 or 5 toxicities in patients with select advanced solid tumors.
SAR444200 Demonstrates Safety, Signals of Clinical Activity in Advanced GPC3+ HCC, Other Solid Tumors
March 11th 2025, 7:13pm
SAR444200-mediated targeting of GPC3-expressing solid tumors was safe and showed early signs of antitumor activity in a phase 1/2 study.
SAR443216 Engages HER2 With Manageable Toxicity in Advanced HER2+ Solid Tumors
March 11th 2025, 5:42pm
ESMO Targeted Anticancer Therapies Congress
The feasibility and safety of treatment with SAR443216 support the further investigation of this agent in patients with advanced HER2-positive tumors.
First-Line T-DXd ± Pertuzumab Yields Durable Responses in HER2+ Metastatic Breast Cancer
March 10th 2025, 7:41pm
ESMO Targeted Anticancer Therapies Congress
T-DXd with or without pertuzumab produced responses in first-line, HER2-positive metastatic breast cancer.
Dato-DXd Plus Durvalumab ± Carboplatin Delivers Antitumor Activity in Advanced NSCLC
March 10th 2025, 7:30pm
ESMO Targeted Anticancer Therapies Congress
Frontline treatment with datopotamab deruxtecan plus durvalumab with/without carboplatin proved active in advanced NSCLC without actionable alterations.
Dr Richardson on the Role of Triplet Regimens in Newly Diagnosed Myeloma
March 10th 2025, 6:28pm
Paul G. Richardson, MD, discusses the role of triplet regimens as the current standard of care in newly diagnosed multiple myeloma.
Neratinib Generates CNS Responses Across HER2+ Breast Cancer Brain Metastases Subgroups
March 10th 2025, 4:51pm
PER® Miami Breast Cancer Conference
Neratinib-containing combinations are consistently effective across CNS end points in patients with HER2-positive breast cancer brain metastases.
SERDs, PROTAC, and CERANs Offer Hope Following ET/CDK4/6 Inhibitor Resistance in Breast Cancer
March 9th 2025, 3:45pm
PER® Miami Breast Cancer Conference
Promising new agents are in development to address the unmet need resulting from resistance to endocrine therapy plus CDK4/6 inhibition in breast cancer.